Patents by Inventor Johannes Wirenfeldt Vad Pedersen
Johannes Wirenfeldt Vad Pedersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11860165Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: GrantFiled: June 18, 2021Date of Patent: January 2, 2024Assignee: GO Therapeutics, Inc.Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
-
Publication number: 20220065862Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: ApplicationFiled: June 18, 2021Publication date: March 3, 2022Applicant: GO THERAPEUTICS, INC.Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
-
Patent number: 11067578Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: GrantFiled: October 16, 2018Date of Patent: July 20, 2021Assignee: GO Therapeutics, Inc.Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
-
Publication number: 20190101541Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: ApplicationFiled: October 16, 2018Publication date: April 4, 2019Applicant: GO THERAPEUTICS, INC.Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
-
Patent number: 10139414Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: GrantFiled: March 6, 2017Date of Patent: November 27, 2018Assignee: GO THERAPEUTICS, INC.Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
-
Publication number: 20170322219Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.Type: ApplicationFiled: March 6, 2017Publication date: November 9, 2017Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel